Hemogenyx Pharmaceuticals PLC Broker's Research Note
July 31 2020 - 2:00AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
31 July 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Broker's Research Note
We are pleased to inform investors that the recently published
research note by our corporate broker, SP Angel Corporate Finance
LLP, is available to view on the Company's web site at
https://hemogenyx.com/broker-coverage/ . The note updates SP
Angel's original Initiation of Research note of August 2019.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Peter Redmond, Director peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility and a Belgian subsidiary,
Hemogenyx-Cell SPRL, located in Liège.
Hemogenyx Pharmaceuticals is a pre-clinical stage
biopharmaceutical group developing new medicines and treatments to
bring the curative power of bone marrow transplantation to a
greater number of patients suffering from otherwise incurable
life-threatening diseases. The Company is developing several
distinct and complementary product candidates, as well as a
platform technology that it uses as an engine for novel product
development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx Pharmaceuticals'
technology has the potential to enable many more patients suffering
from devastating blood diseases such as leukemia and lymphoma, as
well as severe autoimmune diseases such as multiple sclerosis,
aplastic anemia and systemic lupus erythematosus (Lupus), to
benefit from bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKKFBDFBKDFOB
(END) Dow Jones Newswires
July 31, 2020 02:00 ET (06:00 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Aug 2023 to Aug 2024